Global Neuromodulation Devices Market: Analyst’s Estimations

Although a relatively new therapy pertaining to the nervous systems – neuromodulation has evolved consistently in the recent past, enabling in altering nerve activities via targeted stimulus delivery such as chemical agents or electrical stimulation. Neuromodulation has proven its worth for the diagnosis of various ubiquitous chronic diseases such as depression and Alzheimer’s disease. On the back of the trend of minimally invasive procedures, the demand for devices that are used for neuromodulation is primed to proliferate. According to the findings of this business intelligence report, the global neuromodulation devices market will be worth US$7.0 billion by the end of 2018, with the demand expanding at a striking CAGR of 14.40% during the forecast period of 2012 to 2018.

Apart from the growing prevalence of neurological disorders, the neuromodulation devices market is gaining traction from increasing population of geriatrics, promising product pipeline, influx of investments from public and private bodies, and expanding application with new indications. On the other hand, lack of trained professionals and poor reimbursement policies in several emerging economies is obstructing the market from flourishing.

The analyst of the report, a healthcare expert with vast experience in researching the commerce of the field, has provided in-depth assessment of the factors that will determine the demand for neuromodulation devices in the near future. The report also contains market segmentations on the basis of technology and application as well as showcases demand potential of every important region and country across the globe. It concludes with a featured chapter on the competitive landscape, wherein a number of prominent companies of this market have been evaluated and analyzed for their shares and recent business decisions.

Spinal Cord Stimulation Key Technology Segment

Technology-wise, the market for neuromodulation devices has been segmented into gastric electric stimulation devices, vagus nerve stimulation devices, sacral nerve stimulation devices, deep brain stimulation devices, and spinal cord stimulation medical devices. In the near future, spinal cord stimulation segment is expected to make strong profits as it is used in the treatment of various chronic pain. The FDA has recently given approvals to a number of spinal cord stimulation technologies, such as St. Jude Medical’s Proclaim Elite SCS and Nervo Corporation’s Senza SCS system. Some of the newer indications that are supported by SCS are refractory angina pectorsis, failed back surgery syndrome, and complex regional pain syndrome. That being said, the analyst of the report has foreseen the deep brain stimulation (DBS) segment to expand at a stronger growth rate, feeding off new indications such as treatment resistant depression, obsessive compulsive disorder, and Alzheimer’s type dementia.

Technology-wise, the neuromodulation devices market has been bifurcated into Boston Scientific’s Precision Spinal Cord Stimulation System, Jude Medical’s Eon Mini Neurostimulator System, Medtronic’s Spinal Cord and Deep Brain Neurostimulation Systems, Codman & Shurtleff’s Medstream System, Cyberonics’ VNS Therapy System, Nevro’s Senza System for Spinal Cord Stimulation, IntraPace’s Abiliti System, and Medtronic’s Enterra Therapy System.

The U.S. Remains Key Country-wide Market

Geographically, North America continues to be the region with maximum demand potential, which primarily comes from the U.S. As of 2018, North America accounts for well over half of the total demand for neuromodulation devices, which can also be attributed to strong prevalence of depression and other chronic pains across the increasing geriatric population. However, Asia Pacific is another region with great potential owing to its large population base, constituted by the emerging economies of China and India.

St. Jude Medical, Medtronic, Cyberonics, Nevro, Boston Scientific Group, Codman and Shurtleff, Integra, Cervel Neurotech Inc., Uroplasty, IntraPace, and Neuronetics Inc. are some of the key companies currently ahead of the curve in the global neuromodulation devices market.

Neuromodulation devices are used to carry out a process by which a neuron uses one or more neurotransmitters to regulate other populations of neurons. Neuromodulation is a physiological process by which nervous activity is regulated by controlling the physiological levels of several classes of neurotransmitters. One of the fastest growing sectors of the medical devices market, the neuromodulation devices market is estimated to reach a value of US$7.1 bn by 2018, expanding at a CAGR of 14.4% in the period from 2012 to 2018.

Neuromodulation devices are used to provide relief to a patient through modulation or alteration of nervous system function. Neuromodulation functions by stimulating the nerves to produce responses that are natural or by the application of small doses of medicines directly at the site where required. Due to an increase in the adoption of minimally invasive treatment options and medical tourism, the market for neuromodulation devices is expected to grow in the next decade. 

The report addresses questions related to the neuromodulation devices market such as the details about the various segments and sub-segments of the neuromodulation devices market, the current and future trends, the growth drivers, and the factors inhibiting the market. Collated by expert market analysts, the study can be used for expansion, competition monitoring, and for investing in the neuromodulation devices market. 

Overview of the Neuromodulation Devices Market

The global neuromodulation devices market is segmented on the basis of technology, application, and geography. On the basis of geography, the global neuromodulation devices market is segmented into Asia Pacific, Europe, North America, and Rest of the World. Out of these regions, North America dominated the market in 2011, accounting for 65% of the global neuromodulation devices market, and being valued at US$1.8 bn. Asia Pacific is expected to expand at a CAGR of over 15% between 2012 and 2018, owing to the rising demand for neuromodulation devices from developing nations. 

The major growth drivers of the global neuromodulation devices market include the rising prevalence of chronic diseases, rising geriatric population, rising vulnerability to acquire diseases such as Parkinson’s and Alzheimer’s, and technological advancements in neuromodulation devices, making them effective as an add-on therapy. The rising prevalence of lifestyle-induced illnesses such as obesity or depression, increase in the demand for minimally invasive surgeries, increasing consumer expenditure, and an increase in the funds to conduct studies are driving the global market for neuromodulation devices. 

The market’s growth is likely to be inhibited by the changing technological landscape, the availability of alternate treatment procedures, and the side effects and risks associated with the use of neuromodulation devices. Other restraining factors include getting FDA approvals and stringent government regulations that may hamper the market for the forecast period. 

Key Players in the Neuromodulation Devices Market:

The leading players in the neuromodulation devices market that have been profiled and analyzed in the report are: Uroplasty, Codman and Shurtleff, Cervel Neurotech Inc., IntraPace, Nevro , Medtronic, Boston Scientific Group, Integra, St. Jude Medical, Neuronetics Inc., and Cyberonics.
 
Segmentation by Technology Type:

  • Spinal cord stimulation medical devices
  • Deep brain stimulation devices
  • Sacral nerve stimulation devices
  • Vagus nerve stimulation devices
  • Gastric electric stimulation devices. 

Segmentation by Application Area:

  • Medtronic’s Spinal Cord and Deep Brain Neurostimulation Systems
  • St. Jude Medical’s Eon Mini Neurostimulator System
  • Boston Scientific’s Precision Spinal Cord Stimulation System
  • Nevro’s Senza System for Spinal Cord Stimulation
  • Cyberonics’ VNS Therapy System
  • Codman & Shurtleff’s Medstream System
  • Medtronic’s Enterra Therapy System
  • IntraPace’s abiliti system.

Segmentation by Geography:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW). 

This report gives you access to decisive data such as:

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments